

Financial reporting relief granted by ASIC

In connection with the Scheme, AVITA Medical applied to the Australian Securities and Investments Commission (**ASIC**) for relief from the requirement for AVITA Medical to prepare and lodge with ASIC an annual report in accordance with Australian International Financial Reporting Standards (**AIFRS**) for the financial year in which the Scheme was implemented.

The reason for AVITA Medical seeking this relief was to reduce the substantial costs, burden and risks associated with the dual financial reporting and related compliance obligations that AVITA Medical currently has in both the United States and Australia as a result of being treated (since 31 December 2019) as a domestic public company in both of these jurisdictions for financial reporting purposes.

AVITA Medical is pleased to announce that ASIC has granted relief so that, if the Scheme is implemented on or before 30 June 2020, AVITA Medical will not be required to prepare and lodge with ASIC an annual report for the financial year ending 30 June 2020 in accordance with AIFRS.

In order to comply with the conditions to the relief:

- AVITA Medical and its Australian subsidiaries will enter into a new deed of cross guarantee with AVITA Therapeutics, Inc. as the new parent entity of the Avita Group on and from the implementation date of the Scheme; and
- AVITA Therapeutics, Inc. will prepare and file with the U.S. Securities and Exchange Commission for the financial year ending 30 June 2020 in respect of the Avita Group an Annual Report on Form 10-K in accordance with U.S. Generally Accepted Accounting Principles (which will be audited) by 31 August 2020.

If the Scheme is implemented on or before 30 June 2020, it is anticipated that the Avita Group will save approximately A\$400,000 in external professional costs as a result of obtaining this relief.